Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stok Raporu

Piyasa değeri: US$271.4m

Aclaris Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Aclaris Therapeutics yıllık ortalama 3.7% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 1.2% annual. Gelirler yılda ortalama 42.4% oranında büyüyor .

Anahtar bilgiler

3.7%

Kazanç büyüme oranı

17.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı42.4%
Özkaynak getirisi-28.4%
Net Marj-136.7%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Gelir ve Gider Dağılımı

Aclaris Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:ACRS Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 2427-3725-40
30 Jun 2432-59270
31 Mar 2431-77300
31 Dec 2331-88320
30 Sep 2321-1153163
30 Jun 2331-105300
31 Mar 2331-96280
31 Dec 2230-87250
30 Sep 2224-82250
30 Jun 226-83250
31 Mar 226-81250
31 Dec 217-91240
30 Sep 217-82220
30 Jun 217-71190
31 Mar 217-65190
31 Dec 206-51210
30 Sep 206-57220
30 Jun 206-69250
31 Mar 204-102270
31 Dec 194-114280
30 Sep 195-118270
30 Jun 195-115260
31 Mar 196-79160
31 Dec 186-82260
30 Sep 185-813313
30 Jun 185-793424
31 Mar 183-864532
31 Dec 172-50190
30 Sep 171-572533
30 Jun 170-502030
31 Mar 170-481631
31 Dec 160-481533
30 Sep 160-421325
30 Jun 160-421028
31 Mar 160-33819
31 Dec 150-23515
30 Sep 150-21315
30 Jun 150-1338
31 Mar 150-1227
31 Dec 140-1127

Kaliteli Kazançlar: ACRS şu anda kârlı değil.

Büyüyen Kar Marjı: ACRS şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ACRS kârlı değildir, ancak son 5 yılda zararlarını yılda 3.7% oranında azaltmıştır.

Büyüme Hızlandırma: ACRS 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ACRS kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 54.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: ACRS hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -28.43% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin